Karan Chhabra, MD MSc (@krchhabra) 's Twitter Profile
Karan Chhabra, MD MSc

@krchhabra

Minimally invasive/bariatric surgeon+researcher trying to make surgery & obesity care more effective+affordable @NYULangone @BellevueHosp

ID: 285872172

linkhttps://med.nyu.edu/faculty/karan-r-chhabra calendar_today21-04-2011 23:15:20

9,9K Tweet

2,2K Takipçi

782 Takip Edilen

Karan Chhabra, MD MSc (@krchhabra) 's Twitter Profile Photo

I’ve started dictating medical things into Dragon, and then copying and pasting them into Microsoft Word. Until I get my own personal scribe.

STITCHES - the Best Papers in General Surgery (@stitchestoday) 's Twitter Profile Photo

Impact of Private Equity on Surgical Practice Consolidation: Analysis of 1,542 Transactions by Sievers MT, Neevel A (...) Chhabra KR et 5 al. in Ann Surg journals.lww.com/annalsofsurger…

Karl Bilimoria (@kbilimoria) 's Twitter Profile Photo

Everyone in HSR should provide feedback about this absurd proposed policy from CMS. ~$60k per year per person to use CMS data is outrageous. It will hurt all research and institutions with limited resources. They should be increasing data availability - not locking up OUR data!

U-M IHPI (@um_ihpi) 's Twitter Profile Photo

We're proud to be the home of Nat’l Clinician Scholars Program at U-M IHPI, one of the best training programs for #healthservicesresearch in the U.S., in one of the best cities in the U.S.! If you're a physician or doctoral-level nurse nearing the end of training, learn more: tinyurl.com/NCSPinfoMay9

Pooja U Neiman, MD MPA (@poojaneiman) 's Twitter Profile Photo

.Ali Salim, MD Karan Chhabra, MD MSc and Sarabeth Spitzer We put this together after the ACS hosted a Trauma Policy session last year — hope it spurs internal discussions about how policy and its implementation can be used to further improve trauma care

Thomas Tsai, MD, MPH (@thomasctsai) 's Twitter Profile Photo

Anecdotally we've been hearing about the decline in bariatric surgery as patients opt for GLP-1 treatments But what do the data show? Ateev Mehrotra and I decided to answer this question in a new JAMA Network Open study jamanetwork.com/journals/jaman…

SAGES is in Tampa in 2026! (@sages_updates) 's Twitter Profile Photo

We're excited to announce that renowned surgeon, humanitarian and recently recognized one of Time's most influential people, Dr. Robert Montgomery as one of our keynote speakers at SAGES 2026 in Tampa. Read more about Dr. Montgomery at time.com/collections/10…

We're excited to announce that renowned surgeon, humanitarian and recently recognized one of Time's most influential people, Dr. Robert Montgomery as one of our keynote speakers at SAGES 2026 in Tampa. Read more about Dr. Montgomery at time.com/collections/10…
Karan Chhabra, MD MSc (@krchhabra) 's Twitter Profile Photo

Fun morning chatting with Doctor Radio on SiriusXM about getting obesity care to those who need it! Interview will be re-aired today at 4p ET and again Sunday at 4p ET siriusxm.com/channels/docto…

Fun morning chatting with <a href="/NYUDocs/">Doctor Radio</a> on <a href="/SIRIUSXM/">SiriusXM</a> about getting obesity care to those who need it! 

Interview will be re-aired today at 4p ET and again Sunday at 4p ET 

siriusxm.com/channels/docto…
Ali Aminian (@ali_aminian_md) 's Twitter Profile Photo

Real world data presented by Karan Chhabra, MD MSc group at #ASMBS2025 Weight loss after 2 years: ✴️ Gastric bypass: 26% ✴️ Sleeve gastrectomy: 23% ✴️ Tirzepatide: 8% ✴️ Semaglutide: 5%

Real world data presented by <a href="/krchhabra/">Karan Chhabra, MD MSc</a> group at #ASMBS2025

Weight loss after 2 years:

✴️ Gastric bypass: 26%

✴️ Sleeve gastrectomy: 23%

✴️ Tirzepatide: 8%

✴️ Semaglutide: 5%
Karan Chhabra, MD MSc (@krchhabra) 's Twitter Profile Photo

Thanks TODAY for covering our ASMBS presentation on the real-world outcomes of GLP1RAs and bariatric surgery! Appreciated the thoughtful discussion about how to individualize obesity treatment Dr. Natalie Azar today.com/health/diet-fi…

Thanks <a href="/TODAYshow/">TODAY</a> for covering our <a href="/ASMBS/">ASMBS</a> presentation on the real-world outcomes of GLP1RAs and bariatric surgery! Appreciated the thoughtful discussion about how to individualize obesity treatment <a href="/drnatalietv/">Dr. Natalie Azar</a> 

today.com/health/diet-fi…
Karan Chhabra, MD MSc (@krchhabra) 's Twitter Profile Photo

Super proud of our NYU Langone Health research fellow Avery Brown who capped off his fantastic year with the first talk at the ASMBS top papers session on comparative effectiveness of bariatric surgery and GLP1RAs. Loved the NYU Langone Surgery NYC Health + Hospitals/Bellevue turnout!

Super proud of our <a href="/nyulangone/">NYU Langone Health</a> research fellow Avery Brown who capped off his fantastic year with the first talk at the <a href="/ASMBS/">ASMBS</a> top papers session on comparative effectiveness of bariatric surgery and GLP1RAs.  Loved the <a href="/NYULH_Surgery/">NYU Langone Surgery</a> <a href="/BellevueHosp/">NYC Health + Hospitals/Bellevue</a> turnout!
Karan Chhabra, MD MSc (@krchhabra) 's Twitter Profile Photo

Equally proud of our NYU Grossman School of Medicine medical student Elizabeth Li who presented in the same #asmbs2025 Top Papers session - her findings on the (disappointing) safety of DOACs after bariatric surgery have already changed my practice!

Equally proud of our <a href="/nyugrossman/">NYU Grossman School of Medicine</a> medical student Elizabeth Li who presented in the same #asmbs2025 Top Papers session - her findings on the (disappointing) safety of DOACs after bariatric surgery have already changed my practice!
Michael "Mike" Albert, MD (@michaelalbertmd) 's Twitter Profile Photo

🚨 GLP-1s vs Surgery: Who Wins Long Term? - - - A new 2-year comparative study from NYU Langone just dropped—and the results are clear: 📊 Bariatric Surgery vs GLP-1s (semaglutide/tirzepatide): 🔹 25.7% total body weight loss with surgery vs 5.3% with GLP-1s (intention-to-treat)

🚨 GLP-1s vs Surgery: Who Wins Long Term?
- - -
A new 2-year comparative study from NYU Langone just dropped—and the results are clear:

📊 Bariatric Surgery vs GLP-1s (semaglutide/tirzepatide):
🔹 25.7% total body weight loss with surgery vs 5.3% with GLP-1s (intention-to-treat)
NYU Langone Surgery (@nyulh_surgery) 's Twitter Profile Photo

At the 2025 ASMBS Annual Meeting, our very own experts Dr. Ren-Fielding; Karan Chhabra, MD MSc; Manish Parikh, MD; Megan Jenkins; and Tanuja Damani, MD, shared new research on bariatric outcomes, GLP-1 comparisons, and esophageal care. Leading the way in surgical excellence. Read more:

At the 2025 ASMBS Annual Meeting, our very own experts <a href="/DrRenFielding/">Dr. Ren-Fielding</a>; <a href="/krchhabra/">Karan Chhabra, MD MSc</a>; Manish Parikh, MD; <a href="/meganjenkinsmd/">Megan Jenkins</a>; and Tanuja Damani, MD, shared new research on bariatric outcomes, GLP-1 comparisons, and esophageal care. Leading the way in surgical excellence. Read more:
Beverly G. Tchang, MD (@bevtchangmd) 's Twitter Profile Photo

😮 Wow. Connecticut just passed a law effectively pursuing “eminent domain” of #GLP1s 👉finance.yahoo.com/news/connectic… “The new law calls for the Commissioner of Social Services to petition the US Health and Human Services Department (HHS) Secretary Robert F. Kennedy Jr. to exercise